{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": {
    "pdf_name": "Liu_et_al.__2024_",
    "source_pdf": "data/clinical_files/Liu et al. (2024).pdf",
    "total_pages": 13,
    "total_blocks": 146,
    "total_characters": 36717
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 3,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "a cell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4). RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "relevance_explanation": "This quote explicitly states that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4), directly supporting the first part of the claim."
    },
    {
      "id": 2,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3N2) virus than ccIIV4 and IIV4.",
      "relevance_explanation": "This quote provides direct evidence that RIV4 (Flublok), which contains 3x the HA antigen, resulted in greater immunogenicity (higher neutralizing and HA head binding antibodies) compared to standard-dose vaccines, supporting the second part of the claim."
    },
    {
      "id": 3,
      "quote": "For A (H3N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody response in both age groups, it also significantly increased the quantity of the total A (H3N2) cell HA head binding antibodies (Fig. 4A, Fig. S1A).",
      "relevance_explanation": "This quote further supports the claim by stating that RIV4 (Flublok) led to a significant increase in both the quality and quantity of antibody responses, indicating greater immunogenicity compared to standard-dose vaccines."
    }
  ],
  "model_used": "gpt-4.1"
}